Dandrit is given a chance to measure up the competition at the Cancer Vaccine Conference in Boston late june…
Speakers are amongst others: dendreon, Bristol-Myers Squibb, Immunovaccine, Novartis, AstraZeneca, all among the top tier cancer vaccine companies of the world
the whole program is available here:
http://medicoinvestor.com/wp-content/uploads/2012/06/agenda.pdf
DanDrit will be represented by Dr. Eric Leire, who will be talking about challenges and design of phase II Clinical Trials, and participating in a panel discussion afterwards
This is a pat on the shoulder and a major acknowledgement of the potential of Dandrit… I suspect this will be followed this week by the completion of the Due Dilligence of Dandrit.
